"Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage " by Matthew E. Levy, Anya Agopian et al.
 

Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?

Document Type

Journal Article

Publication Date

3-1-2021

Journal

Journal of Acquired Immune Deficiency Syndromes

Volume

86

Issue

3

Inclusive Pages

e80-e82

DOI

10.1097/QAI.0000000000002557

Peer Reviewed

1

Find in your library

Plum Print visual indicator of research metrics
PlumX Metrics
  • Citations
    • Citation Indexes: 12
    • Policy Citations: 1
  • Usage
    • Abstract Views: 21
  • Captures
    • Readers: 29
see details

Share

COinS